Skye Bioscience (SKYE) Proxy filing summary

Executive summary

• 2025 marked significant clinical progress, with nimacimab advancing to proof-of-concept in obesity and showing promising results in combination with semaglutide, including sustained weight loss and favorable safety data over 52 weeks.

• The company is preparing for a Phase 2b trial, incorporating FDA feedback, and exploring higher-dose regimens and advanced delivery technologies to optimize efficacy and safety.

• Expansion into antibody-peptide conjugate programs supports a multi-mechanism metabolic platform, aiming for real-world impact in obesity and related diseases.

• Financial discipline and focused execution remain priorities, with additional data and platform advancements expected in 2026.

Voting matters and shareholder proposals

• Six directors are nominated for election to one-year terms expiring at the 2027 annual meeting.

• Proposals include ratification of CBIZ CPAs P.C. as independent auditor, approval to increase authorized common stock from 100M to 300M shares, and an advisory vote on executive compensation.

• The board recommends voting in favor of all proposals.

Board of directors and corporate governance

• The board consists of six members, with a majority deemed independent under Nasdaq rules.

• Roles of CEO and Chairman are separated for balanced oversight.

• Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent members and written charters.

• Anti-hedging, compensation recoupment, and insider trading policies are in place.

• Director compensation includes cash and equity, with annual and initial option awards and change-in-control provisions.